HC Wainwright Rates SAB Biotherapeutics (SABS) buy
HC Wainwright maintains its optimistic outlook on SABS with a reiterated buy rating, a 200.30% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
HC Wainwright rated SAB Biotherapeutics, Inc. ($SABS) "buy" with a $10 price target on June 15, 2026.
Since the rating, $SABS is up 0.8% after 1 week, down 7.2% after 1 month and down 35.1% to date (from the $3.90 close on Jun 15, 2026).
SABS
SAB Biotherapeutics, Inc.
Key Points
- HC Wainwright reiterated its buy rating for SABS on June 15, 2026, with a price target of $10.
- HC Wainwright's $10 price target implies 200.30% upside from SAB Biotherapeutics, Inc.'s ($SABS) current $3.33 share price.
- SABS shares traded at $3.33, reflecting ongoing analyst confidence despite current market conditions.
- Recent insider buying includes significant purchases by executives, with the CEO acquiring 4.8 million shares.
Get $SABS trade alerts by text
We text you when insiders, Congress or big funds trade $SABS. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated SAB Biotherapeutics, Inc. alert may contain errors. Disclosures
On June 15, 2026, HC Wainwright reiterated its buy rating for SABS, setting a price target of $10. Analyst Emily Bodnar expressed confidence in the company's prospects despite current market challenges. Shares of SABS were trading at $3.33 at the time of the rating.
Other Institutional Activity in SABS
Vivo Capital, LLC maintained its position in SABS, holding steady at 11.42 million shares valued at about $43.74 million. Caligan Partners LP established a new stake with 7.97 million shares worth approximately $30.51 million. Perceptive Advisors LLC significantly increased its holdings by 5.63 million shares, bringing its total to 6.43 million shares valued at $24.63 million. Meanwhile, RA Capital Management, L.P. and Commodore Capital LP held their positions steady, each with 4.40 million shares valued at $16.86 million.
SAB Biotherapeutics, Inc. Stock Down 5.1%
SABS shares are currently trading at $3.33. The stock has been receiving attention from several analysts, with a recent reiterated buy rating from HC Wainwright. While the company's market cap and other financial metrics were not detailed, the stock's price target suggests potential upside from its current trading level.
$SABS price target
SAB Biotherapeutics, Inc. daily closes and this analyst's $10 target. Not advice.
Insider Buying and Selling at SAB Biotherapeutics, Inc.
Recent insider transactions at SABS include significant purchases on February 3, 2026. Chief Financial Officer Lucy To and Chief Operating Officer Christoph Lawrence Bausch each acquired 2.4 million shares, while Chief Medical Officer Alexandra Kropotova and CEO Samuel Reich bought 2.4 million and 4.8 million shares, respectively. These transactions were not part of any pre-planned trading program.
Analysts Set New Price Targets
On June 15, 2026, HC Wainwright reiterated its buy rating for SABS with a $10 price target. Earlier, on May 22, 2026, Citigroup initiated coverage with a buy rating and an $11 target. Jefferies also started coverage with a buy rating and an $11 target on May 20, 2026. The consensus among analysts is positive, with a mean target price reflecting optimism about SABS's future performance.
Bottom Line
HC Wainwright's reiterated buy rating for SABS highlights continued analyst confidence in the company's potential, as reflected in its $10 price target. This optimism is mirrored by recent institutional activity, with significant stake increases by several funds. Insider buying by key executives further underscores confidence in SABS's prospects. As always, it's important to remember that analyst ratings and insider transactions are just part of the broader picture investors should consider.
Related Filing Alerts
Source: HC Wainwright's rating change on $SABS (Jun 15, 2026). Written by software, not financial advice. How we make alerts